🇺🇸 FDA
Patent

US 9663496

AMPK-activating heterocyclic compounds and methods for using the same

granted A61PA61P1/04A61P1/14

Quick answer

US patent 9663496 (AMPK-activating heterocyclic compounds and methods for using the same) held by Rigel Pharmaceuticals, Inc. expires Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue May 30 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 25 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P1/04, A61P1/14, A61P1/16, A61P1/18